Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $69.00, but opened at $60.2750. Basilea Pharmaceutica shares last traded at $60.2750, with a volume of 12 shares.
Basilea Pharmaceutica Stock Performance
The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average price of $68.22 and a 200 day moving average price of $67.85.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
- Palantir’s AIPCon Shows Why Customers Are Fueling the Bull Case
- Chewy’s Growth Engine Is Stronger Than the Market Thinks
- Nebius Group’s £1.7 Billion UK Expansion Fuels Bullish Case Despite the Pullback
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
